Island Pharmaceuticals

ILA.AX

12 October 2023

Clinical program to start

NEED TO KNOW

- FDA clearance to begin SAD¹ clinical study
- SAD study to further optimise trial protocol
- ILA is repurposing drugs lower safety risk

ILA's ISLA-101 receives FDA clearance for SAD clinical study: The FDA has lifted its clinical hold and granted ILA an Investigational New Drug (IND) clearance for the company to undertake a Single Ascending Dose (SAD) study. Hospital Research Ethics Committee (HREC) approval is also required.

Broadened expertise/ tax advantage: ILA has engaged an Australian clinical trials facility and a Clinical Research Organisation (CRO) to run and monitor the SAD study. The CRO brings additional expertise and as an Australian-based clinical trial, ILA is entitled to a 43.5% R&D tax rebate.

Investment Thesis

Repurposed drugs offer significant advantages: In comparison to the development of 'first in human' drugs, ILA is repurposing drugs for viral illnesses. The strategy brings potential advantages including lower development costs, faster timelines and lower safety risk.

No approved treatment for Dengue Fever: The first FDA approved Dengue Fever drug may be eligible for Priority Review Voucher, with current value of ~US\$100m.

ISLA-101 has the potential to be used in multiple indications: The mechanism of action of ISLA-101 supports potential application in Yellow Fever virus, West Nile virus, Japanese encephalitis and Zika virus.

Valuation

MST's 12 month forward valuation of A\$22m, (previously \$29m) is based on the average market capitalisation of a cohort of ASX-listed biotechnology companies in Phase 1/2 trials, a similar stage of development. Upside risk presents with FDA confirmation for the commencement of the Phase 2a trial. MST also notes that data from the SAD study may allow for adaption of the planned clinical program potentially bringing time savings and reduced costs.

Risks & Sensitivities

The valuation is subject to the usual drug development risks; regulatory approval, market entry, market size, market share, pricing, drug supply, competitor products, timing and potential licensing metrics – all may differ from MST assumptions, presenting upside/downside risk. MST notes realisation of the valuation over the short term will be difficult but expects positive trial results in FY24 to see a re-rating of the stock.



A research platform of MST Financial

Biotechnology & Plasma Products

Rosemary Cummins, Senior Analyst rosemary.cummins@mstaccess.com.au



Antiviral therapeutics


ASX listed Island Pharmaceuticals (ILA.AX) is a drug research company, focused on repurposing drugs to prevent and/or treat viral illnesses. Repurposed drugs potentially offer shorter, lower cost routes to market and a higher probability of approval. ILA's first target is dengue infection. Its lead drug candidate, ISLA-101 (fenretinide), offers application in a number of other viral related illnesses. ILA aims to build a strong pipeline of drug candidates through in-licensing agreements and acquisition.

www.islandpharmaceuticals.com

Valuation	A\$0.18ps (prev \$0.36)
Current price	A\$0.08ps
Market cap	A\$6.7m
Cash on hand	A\$2.0m at FY23 end

Upcoming Catalysts and Newsflow

Period	
FY24	1st Subject enrolled in SAD
FY24	SAD results
FY24	Confirmation/commencement Phase 2a trial
Share I	Price (A\$)



Source: FactSet, MST Access

MST Access has been engaged and paid by the company covered in this report for ongoing research coverage. Please refer to full disclaimers and disclosures.

¹ Single Ascending Dose

Report prepared by MST Access, a registered business name of MST Financial services ABN 617 475 180 AFSL 500 557

Figure 1: Financial Summary

Year end 30 June		
MARKET DATA		
Share Price	A\$	0.08
52 week low / high	A\$	0.25-0.07
Valuation (12 month forward)	A\$	0.18
Market capitalisation	A\$m	6.7
Shares on issue	m	81.3
Options	m	14.4
Other equity	m	40.0
Potential Shares on issue (diluted)	m	135.7

INVESTMENT FUNDAMENTALS		FY22	FY23	FY24E	FY25E	FY26E	F
EPS Reported (undiluted)	¢	(3.2)	(3.5)	(3.5)	(2.5)	(2.2)	F
EPS Underlying (undiluted)	¢	(3.2)	(3.5)	(3.5)	(2.5)	(2.2)	E
Underlying EPS growth	%	n/m	n/m	n/m	n/m	n/m	E
P/E Reported (undiluted)	x	n/m	n/m	n/m	n/m	n/m	[
P/E at Valuation	х	n/m	n/m	n/m	n/m	n/m	E
Dividend	¢	-	-	-	-	-	I
Payout ratio	%	0%	0%	0%	0%	0%	F
Yield	%	-	-	-	-	-	1

KEY RATIOS (A\$)		FY22	FY23	FY24E	FY25E	FY26E
Forecast year end shares	m	81	81	106	106	121
Market cap (Y/E / Spot)	\$m	6.5	6.5	8.5	8.5	9.7
Net debt /(cash)	\$m	(4.8)	(2.0)	(3.3)	(0.7)	(3.1)
Enterprise value	\$m	1.7	4.5	5.2	7.8	6.6
EV/Sales	х	n/a	n/a	n/a	n/a	n/a
EV/EBITDA	x	(0.7)	(1.6)	(1.4)	(3.0)	(2.5)
EV/EBIT	х	(0.7)	(1.6)	(1.4)	(3.0)	(2.5)
Net debt / Enterpprise Value	х	(2.8)	(0.4)	(0.6)	(0.1)	(0.5)
Gearing (net debt / EBITDA)	x	1.8	0.7	0.9	0.3	1.2
Operating cash flow per share	\$	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)
Price to operating cash flow	x	(3.5)	(2.4)	(2.3)	(3.3)	(3.7)
Free cash flow	\$m	(1.9)	(2.7)	(3.7)	(2.6)	(2.6)
Free cash flow per share	\$	(0.02)	(0.03)	(0.03)	(0.02)	(0.02)
Price to free cash flow	x	(3.5)	(2.4)	(2.3)	(3.3)	(3.7)
Free cash flow yield	%	n/m	n/m	n/m	n/m	n/m
Book value / share	\$	0.05	0.02	0.03	0.01	0.03
Price to book (NAV)	x	1.5	3.6	2.7	12.2	3.2
NTA / share	\$	0.05	0.02	0.03	0.01	0.03
Price to NTA	x	1.5	3.6	2.7	12.2	3.2
EBITDA margin	%	n/m	n/m	n/m	n/m	n/m
ROE (Average Equity)	%	n/m	n/m	n/m	n/m	n/m
ROA (EBIT)	%	n/m	n/m	n/m	n/m	n/m
Interest cover (EBIT / net interest)	х	n/m	n/m	n/m	n/m	n/m



PROFIT AND LOSS (A\$)		FY22	FY23	FY24E	FY25E	FY26E
Revenue & Other Income	\$m	-	0.0	-	-	-
Expenses	\$m	(2.6)	(2.8)	(3.7)	(2.6)	(2.7)
EBITDA	\$m	(2.6)	(2.8)	(3.7)	(2.6)	(2.7)
D&A	\$m	-	-	-	-	-
EBIT	\$m	(2.6)	(2.8)	(3.7)	(2.6)	(2.7)
Interest	\$m	-	(0.0)	-	-	0.1
Pre-tax Profit	\$m	(2.6)	(2.8)	(3.7)	(2.6)	(2.6)
Tax	\$m	-	-	-	-	-
Underlying NPAT	\$m	(2.6)	(2.8)	(3.7)	(2.6)	(2.6)

BALANCE SHEET (A\$)		FY22	FY23	FY24E	FY25E	FY26E
Cash	\$m	4.8	2.0	3.3	0.7	3.1
Receivables	\$m	0.0	0.0	0.0	-	-
Inventory	\$m	-	-	-	-	-
PPE	\$m	-	-	-	-	-
Other	\$m	0.1	0.0	0.0	0.0	0.0
Total Assets	\$m	4.9	2.0	3.4	0.7	3.1
Creditors	\$m	0.5	0.2	0.2	-	-
Borrowings	\$m	-	-	-	-	-
Other	\$m	0.0	0.1	0.1	0.1	0.1
Total Liabilities	\$m	0.6	0.3	0.3	0.1	0.1
Shareholder's equity	\$m	4.3	1.8	3.1	0.7	3.1

CASH FLOW (A\$)		FY22	FY23	FY24E	FY25E	FY26E
Receipts from customers	\$m	-	-	-	-	-
Payments to suppliers and employees	\$m	(1.9)	(2.7)	(3.7)	(2.6)	(2.7)
R&D rebate	\$m	-	-	-	-	-
Milestones	\$m	-	-	-	-	-
Interest	\$m	-	0.0	-	-	0.1
Tax	\$m	-	-	-	-	-
Other	\$m	-	-	-	-	-
Operating cash flow	\$m	(1.9)	(2.7)	(3.7)	(2.6)	(2.6)
Capex	\$m	-	-	-	-	-
Acquisitions	\$m	-	-	-	-	-
Other	\$m	-	-	-	-	-
Investing cash flow	\$m	-	•		-	-
Borrowings	\$m	-	(0.2)	-	-	-
Equity	\$m	-	-	5.0	-	5.0
Dividend	\$m	-	-	-	-	-
Financing cash flow	\$m	-	(0.2)	5.0	-	5.0
Change in Cash / FX	\$m	(1.9)	(2.9)	1.3	(2.6)	2.4
Year end cash	\$m	4.8	2.0	3.3	0.7	3.1

Source: MST, Company Reports

Report prepared by MST Access, a registered business name of MST Financial services ABN 617 475 180 AFSL 500 557

MST Access has been engaged and paid by the company covered in this report for ongoing research coverage. Please refer to full disclaimers and disclosures.

Phase 2 trial Update

- In December 2022, ILA submitted its Investigational New Drug application to the US FDA for approval to commence its Phase 2a trial.
- In January 2023, the FDA raised a number of queries and placed a clinical hold on the trial.
- In February 2023, the FDA provided further detail and requested that Island Pharmaceuticals (ILA) undertake a Single Ascending Dose (SAD) trial. The SAD trial will progressively measure the blood concentration levels of ISLA-101, following administration of increasing doses. The aim is to ensure the dose for the Phase 2a trial will achieve the blood concentration levels that are predicted to be effective against the dengue virus.
- In April 2023, ILA filed its response to the FDA after a review of all aspects of the original IND submission.
- In May 2023, ILA announced that the FDA had lifted the clinical hold and granted an Investigational New Drug approval for the SAD trial. The Phase 2a trial is planned to follow on dose confirmation.
- In September 2023, ILA announced that its preparatory work was essentially completed and that it
 plans to start the SAD trial in October, pending HREC approval.

Clinical trial program to start on confirmation of dose

ILA has announced that it plans to start the clinical trial program of its repurposed drug, ISLA-101 (fenretinide) in October, subject to Hospital Research Ethics Committee approval. The trial program was placed on a 'Clinical Hold' in January 2023, when the FDA raised queries regarding the trial design. The revised trial program includes a SAD study.

ILA plans to undertake a human challenge trial, whereby the subjects are exposed to the dengue fever pathogen. A key concern is the exposure of a 'healthy' subject to a potentially serious disease. The SAD study aims to confirm that administered doses will achieve an efficacious level of the drug in the blood. ILA has determined the dosing formula based on its own research and previous preclinical/ clinical data. As a repurposed drug, the resources are deep with data relating to safety and dosing available from over 45 ISLA-101/fenretinide trials in diseases including cancer, macular degeneration and Cystic Fibrosis.

The SAD study will be a dose escalation study with four cohorts of increasing dose levels. The 'starting' dose will be increased until the blood concentrations of ISLA-101 reach the pre-determined level, referred to as the Maximum Tolerated Dose (MTD). A Safety Review Committee will review each cohort's data to determine if it is safe to move to the next cohort with a higher dose. The trial is expected to complete dosing in late CY23, with read out of the trial results to follow in early CY24.

On confirmation of the dose, ILA will seek regulatory approval to commence its PEACH2a trial, also a human dengue challenge trial. ILA has appointed Scientia Clinical Research, an Australian clinical trials facility and Beyond Drug Development, a Contract Research Organisation to conduct the study. The undertaking of the trial in Australia allows for ILA to fully leverage Australia's Research & Development Tax Incentive scheme. The scheme allows for a 43.5% R&D tax rebate.

Impact for ILA

ILA had planned to start its Phase 2a trial in H2FY22 with results planned for H1FY23. Regulatory queries have brought significant delays with additional costs and longer lead time to potential revenue flows. From a financial perspective, ILA reported cash of ~ \$2m at FY23 end.

MST notes that there have been changes to the competitive landscape over this period. The unmet medical need attracts strong interest. A number of prospective therapies including both preventative vaccines and therapeutics have been withdrawn over the recent period.

In addition to reducing potential competitors in the marketplace, the smaller competitive field increases the chance of being the first to market. As a tropical disease for which there is no treatment, dengue fever is an FDA-designated Neglected Tropical Disease. As such if ISLA-101 is the first approved treatment in dengue fever by the FDA and it receives a Priority Review, ILA will qualify for a Priority Review Voucher (PRV). PRVs are awarded to pharmaceutical companies for the development and approval of drugs in nominated diseases. The voucher can be used for future drugs that do not meet the qualifying criteria or sold with current estimated pricing of ~US\$100m.

Data from the SAD study that identifies the effective dosing range may allow for the number of cohorts to be reduced. It would offer both cost and time savings.

Reduced competition

Voucher.

increases the odds for a

possible Priority Review

Report prepared by MST Access, a registered business name of MST Financial services ABN 617 475 180 AFSL 500 557

MST Access has been engaged and paid by the company covered in this report for ongoing research coverage. Please refer to full disclaimers and disclosures.

Valuation, Risks, Sensitivities

Company	ASX Ticker	Market Cap (\$m)	Current Phase
Adalta Ltd	1AD-AU	9.3	Completed Phase I trial and starting Phase 2
Chimeric Therapeutics	CHM-AU	13.9	Completed Phase I trial and starting Phase 2
Prescient Therapeutics Ltd	PTX-AU	44.2	Completed Phase I trial and starting Phase 2
PharmAust Limited	PAA-AU	26.9	Ongoing Phase 2 trial
Amplia Therapeutics Ltd	ATX-AU	15.7	Ongoing Phase 2 trial
Actinogen Medical	ACW-AU	44.3	Ongoing Phase 2 trials
Noxopharm	NOX-AU	26.3	Ongoing Phase 2 trials
Immuron Ltd	IMC-AU	17.3	Ongoing Phase 2 trials
Alterity Therapeutics Ltd	ATH-AU	17.1	Ongoing Phase 2 trials
Recce Pharmaceuticals	RCE-AU	89.3	Ongoing Phase 2 trials
KAZIA Therapeutics Ltd	KZA	86.0	Beginning Phase 3

Figure 2: Cohort of ASX-listed biotechs in Phase 1/2 trial

MST's valuation is based on the average market capitalisation of a cohort of ASX listed biotechs in Phase 1/2 trial, a similar stage of development to ISLA-101. In MST's view, there is a rationale for a premium to the Phase 1/2 cohort. Phase 1 and 2 trials focus on safety with early indications of efficacy often included in the Phase 2. As a repurposed drug, ISLA-101 offers strong safety data from over 45 previous clinical trials. However, in MST's view, the premium is unlikely to be recognised in the current investor environment and uncertainty arising from the FDA enquiries.

The valuation approach based on an average of the three Phase 1/2 trials presents a 12-month forward valuation of A\$22m versus current market capitalisation of A\$6.7m. Market confidence on news of the SAD trial outcome and confirmation of the format and regulatory approval for the trial to commence is expected to bring investor reassurance – noting the market themes are likely to predominate.

Upside/downside risks and sensitivities of drug development include clinical trial patient recruitment, timing and costs, regulatory approval and market entry, pricing, market penetration and sales, competitor drugs and potential royalties/licensing payments. MST also acknowledges the current sector investment trends as headwinds in realising the valuation over the short term.

Report prepared by MST Access, a registered business name of MST Financial services ABN 617 475 180 AFSL 500 557 MST Access has been engaged and paid by the company covered in this report for ongoing research coverage. Please refer to full disclaimers and disclosures.

mstaccess.com.au

Methodology & Disclosures

MST Access is a registered business name of MST Financial Services Pty Ltd (ACN 617 475 180 "MST Financial") which is a limited liability company incorporated in Australia on 10 April 2017 and holds an Australian Financial Services Licence (Number: 500 557). This research is issued in Australia through MST Access which is the research division of MST Financial. The research and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. Any advice given by MST Access is general advice only and does not take into account your personal circumstances, needs or objectives. You should, before acting on this advice, financial situation and needs. If our advice relates to the acquisition, or possible acquisition, of a financial product you should read any relevant Product Disclosure Statement or like instrument.

This report has been commissioned by Island Pharmaceuticals Limited and prepared and issued by Rosemary Cummins of MST Access in consideration of a fee payable by Island Pharmaceuticals Limited. MST Access receives fees from the company referred to in this document, for research services and other financial services or advice we may provide to that company.

MST Financial also provides equity capital markets ("ECM") and corporate advisory services through its capital markets division, MST Capital Markets ("MST Capital"). MST Capital provides these services to a range of companies including clients of the MST Access service. As such, MST Capital may in future provide ECM and/or corporate advisory services to the company that is the subject of this research report and, accordingly, may receive fees from the company for providing such services. However, MST Financial has measures in place to ensure the independence of its research division is maintained, including information barriers between its Capital Markets and Research teams. In addition, neither MST Access, not any of its research analysts, receive any financial benefit that is based on the revenues generated by MST Capital Markets or any other division of MST Financial.

The analyst has received assistance from the company in preparing this document. The company has provided the analyst with communication with senior management and information on the company and industry. As part of due diligence, the analyst has independently and critically reviewed the assistance and information provided by the company to form the opinions expressed in the report. Diligent care has been taken by the analyst to maintain an honest and fair objectivity in writing this report and making the recommendation. Where MST Access has been commissioned to prepare content and receives fees for its preparation, please note that NO part of the fee, compensation or employee remuneration paid will either directly or indirectly impact the content provided.

Accuracy of content: All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report and have not sought for this information to be independently certified. Opinions contained in this report represent those of MST Access at the time of publication. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results and estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations.

Exclusion of liability: To the fullest extent allowed by law, MST Access shall not be liable for any direct, indirect or consequential losses, loss of profits, damages, costs or expenses incurred or suffered by you arising out or in connection with the access to, use of or reliance on any information contained in this report. No guarantees or warranties regarding accuracy, completeness or fitness for purpose are provided by MST Access, and under no circumstances will any of MST Financials' officers, representatives, associates or agents be liable for any loss or damage, whether direct, incidental or consequential, caused by reliance on or use of the content.

General Advice Warning

MST Access Research may not be construed as personal advice or recommendation. MST encourages investors to seek independent financial advice regarding the suitability of investments for their individual circumstances and recommends that investments be independently evaluated. Investments involve risks and the value of any investment or income may go down as well as up. Investors may not get back the full amount invested. Past performance is not indicative of future performance. Estimates of future performance are based on assumptions that may not be realised. If provided, and unless otherwise stated, the closing price provided is that of the primary exchange for the issuer's securities or investments. The information contained within MST Access Research is published solely for information purposes and is not a solicitation or offer to buy or sell any financial instrument or participate in any trading or investment strategy. Analysis contained within MST Access Research publications is based upon publicly available information and may include numerous assumptions. Investors should be aware that different assumptions can and do result in materially different results.

MST Access Research is distributed only as may be permitted by law. It is not intended for distribution or use by any person or entity located in a jurisdiction where distribution, publication, availability or use would be prohibited. MST makes no claim that MST Access Research content may be lawfully viewed or accessed outside of Australia. Access to MST Access Research content may not be legal for certain persons and in certain jurisdictions. If you access this service or content from outside of Australia, you are responsible for compliance with the laws of your jurisdiction and/or the jurisdiction of the third party receiving such content. MST Access Research is provided to our clients through our proprietary research portal and distributed electronically by MST to its MST Access clients. Some MST Access Research products may also be made available to its clients via third party vendors or distributed through alternative electronic means as a convenience. Such alternative distribution methods are at MST's discretion.

Access & Use

Any access to or use of MST Access Research is subject to the <u>Terms and</u> <u>Conditions</u> of MST Access Research. By accessing or using MST Access Research you hereby agree to be bound by our Terms and Conditions and hereby consent to MST collecting and using your personal data (including cookies) in accordance with our <u>Privacy Policy</u>, including for the purpose of a) setting your preferences and b) collecting readership data so we may deliver an improved and personalised service to you. If you do not agree to our Terms and Conditions and/or if you do not wish to consent to MST's use of your personal data, please do not access this service.

Copyright of the information contained within MST Access Research (including trademarks and service marks) are the property of their respective owners. MST Access Research, video interviews and other materials, or any portion thereof, may not be reprinted, reproduced, sold or redistributed without the prior written consent of MST.